Abstract:
The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ß and advanced glycation-end-products.
Abstract:
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
Abstract:
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
Abstract:
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.
Abstract:
The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid ß and advanced glycation-end-products.
Abstract:
Proteínas aisladas, en particular anticuerpos monoclonales, en particular anticuerpos humanizados, con injertos de CDR, que se unen a una proteína RAGE. Específicamente, estos anticuerpos tienen la capacidad de inhibir la unión de RAGE a sus diversos ligandos. Los anticuerpos, o porciones de los mismos, que se describen en la presente solicitud son de utilidad para el tratamiento de una enfermedad o trastorno caracterizado por, o inducido por, ligandos fisiopatológicos de RAGE, por ejemplo proteínas mal plegadas como el ß amiloide y productos finales de glicosilación avanzada.
Abstract:
Prote¡nas aisladas, en particular anticuerpos monoclonales, en particular anticuerpos humanizados, con injertos de CDR, que se unen a una prote¡na RAGE. Espec¡ficamente, estos anticuerpos tienen la capacidad de inhibir la union de RAGE a sus diversos ligandos. Los anticuerpos, o porciones de los mismos, que se describen en la presente solicitud son de utilidad para el tratamiento de una enfermedad o trastorno caracterizado por, o inducido por, ligandos fisiopatologicos de RAGE, por ejemplo prote¡nas mal plegadas como el beta amiloide y productos finales de glicosilacion avanzada.
Abstract:
Proteínas aisladas, en particular anticuerpos monoclonales, en particular anticuerpos humanizados, con injertos de CDR, que se unen a una proteína RAGE. Específicamente, estos anticuerpos tienen la capacidad de inhibir la unión de RAGE a sus diversos ligandos. Los anticuerpos, o porciones de los mismos, que se describen en la presente solicitud son de utilidad para el tratamiento de una enfermedad o trastorno caracterizado por, o inducido por, ligandos fisiopatológicos de RAGE, por ejemplo proteínas mal plegadas como el ß amiloide y productos finales de glicosilación avanzada.
Abstract:
El tema de la invención se relaciona con proteínas aisladas particularmente anticuerpos monoclonales, los cuales se unen con el receptor de Nogo-66. Específicamente, los anticuerpos tienen la capacidad de inhibir la unión del ligando natural del receptor de Nogo-66 y neutralizar el receptor de Nogo-66. Estos anticuerpos o porciones de los mismos de la invención son útiles par detectar NgR y para inhibir la actividad de NgR, por ejemplo, en un ser humano que padece un trastorno en el que la actividad de NgR o Nogo-66 es perjudicial.
Abstract:
The subject invention relates to isolated proteins, particularly monoclon al antibodies, which bind to the Nogo-66 receptor. Specifically, these antib odies have the ability to inhibit the binding of the natural ligand of the N ogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or por tions thereof of the invention are useful for detecting NgR and for inhibiti ng NgR activity, for example in a human suffering from a disorder in which N gR or Nogo-66 activity is detrimental.